US EPA

7456932 

Journal Article 

New acetylcholinesterase inhibitors for alzheimer's disease 

Mehta, M; Adem, A; Sabbagh, M 

2012 

Yes 

International Journal of Alzheimer's Disease
ISSN: 2090-0252 

English 

10.1155/2012/728983 

Acetylcholinesterase (AChE) remains a highly viable target for the symptomatic improvement in Alzheimer's disease (AD) because cholinergic deficit is a consistent and early finding in AD. The treatment approach of inhibiting peripheral AchE for myasthenia gravis had effectively proven that AchE inhibition was a reachable therapeutic target. Subsequently tacrine, donepezil, rivastigmine, and galantamine were developed and approved for the symptomatic treatment of AD. Since then, multiple cholinesterase inhibitors (ChEI) continue to be developed. These include newer ChEIs, naturally derived ChEIs, hybrids, and synthetic analogues. In this paper, we summarize the different types of ChEIs in development and their respective mechanisms of actions. This pharmacological approach continues to be active with many promising compounds. © 2012 Mona Mehta et al. 

5 (n methyl n propargyl aminomethyl)quinolin 8 yl dimethyl carbamate; 5 (n methyl n propargylaminomethyl)quinolin 8 yl ethylmethyl carbamate; beta carboline; cholinesterase inhibitor; donepezil; esolerine; ferulic acid; galangin; galantamine; Himatanthus lancifolius extract; huperzine A; huperzine B; ladostigil; metrifonate; Nelumbo nucifera extract; phenserine; phenyl 5,6 dimethoxy 1 oxo 2,3 dihydro 1h 2 indenylmethanone; physostigmine; placebo; plant extract; rivastigmine; tacrine; tacrine 8 hydroxyquinoline; tesofensine; tolserine; unclassified drug; Alzheimer disease; anorexia; article; diarrhea; dizziness; drug half life; glaucoma; headache; Himatanthus lancifolius; human; insomnia; medicinal plant; myasthenia gravis; nausea; Nelumbo nucifera; nonhuman; priority journal; seizure; syncope; vomiting